Nivedita L. Rao

Dr. Nivedita L. Rao

Biochemistry, Yenepoya University, Mangalore, India
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
Nivedita L. RaoNivedita L. Rao
Nivedita L. Rao
GKGreeshma B. Kotian
Greeshma B. Kotian
JSJeevan K Shetty
Jeevan K Shetty
BSBhaskara Pillai Shelley
Bhaskara Pillai Shelley
MDMackwin Kenwood Dmello
Mackwin Kenwood Dmello
SSSaiqa Rasool Shah
Saiqa Rasool Shah
Diabetes mellitus, a well-established risk factor for stroke, is related to higher mortality and poorer outcomes following the stroke event. Advanced glycation end products(AGEs), their receptors RAGEs, other ligands, and several other processes contribute to the cerebrovascular pathomechanism interaction in the diabetes–ischemic stroke combination. Critical reappraisal of molecular targets and therapeutic agents to mitigate them is required to identify key elements for therapeutic interventions that may improve patient outcomes. This scoping review maps evidence on the key roles of AGEs, RAGEs, other ligands such as Leukotriene B4 (LTB4), High-mobility group box 1 (HMGB1) nuclear protein, brain–kidney–muscle crosstalk, alternate pathomechanisms in neurodegeneration, and cognitive decline related to diabetic ischemic stroke. RAGE, HMGB1, nitric oxide, and polyamine mechanisms are important therapeutic targets, inflicting common consequences of neuroinflammation and oxidative stress. Experimental findings on a number of existing–emerging therapeutic agents and natural compounds against key targets are promising. The lack of large clinical trials with adequate follow-up periods is a gap that requires addressing to validate the emerging therapeutic agents. Five therapeutic components, which include agents to mitigate the AGE–RAGE axis, improved biomarkers for risk stratification, better renal dysfunction management, adjunctive anti-inflammatory–antioxidant therapies, and innovative neuromuscular stimulation for rehabilitation, are identified. A comprehensive therapeutic strategy that features all the identified components is needed for outcome improvement in diabetic stroke patients.

31 August 2020 in Biomedical Research and Therapy
Verified
Journal Article
Open access
PDF file
SASadaf Ali
Sadaf Ali
Nivedita L. RaoNivedita L. Rao
Nivedita L. Rao
Introduction: Advanced glycation end products (AGEs) and diabetes duration have roles in the development of the vascular complications associated with morbidity and mortality in diabetic patients. The present study was conducted to estimate and find the association between serum fluorescence levels of advanced glycation products with diabetes duration and glycemic control in type 2 diabetic patients. Methods: 46 patients who had diabetic duration of less than ten years and 49 patients with duration more than ten years were included in the study. Serum fluorescence of AGEs was measured using a simple spectrofluorometric method. Correlations of AGEs with diabetes duration, fasting glucose, and glycated hemoglobin levels were analyzed. The incidence of microvascular complications in patients of both groups was examined. Results: Significantly higher serum fluorescent AGE levels (p < 0.001) and higher incidence of microvascular complications (p = 0.000) were found in diabetic patients who had diabetes duration of more than ten years, poorer glycemic control and higher age. Serum levels of fluorescent AGEs showed significant positive correlations with duration of diabetes mellitus, glycated haemoglobin and fasting glucose levels. Conclusion: Screening patients for AGEs, intensive glycemic control, and therapeutic strategies that target molecular mechanisms involving advanced glycation end products are warranted in older patients with longer diabetes duration to minimize their risk of developing complications.

1 November 2020 in Journal of Clinical and Diagnostic Research
Verified
Journal Article
Closed access
SASadaf Ali
Sadaf Ali
Nivedita L. RaoNivedita L. Rao
Nivedita L. Rao
Introduction: Enhanced formation and accumulation of Fluorescent Advanced Glycation End products (F-AGEs) in diabetes mellitus have been linked to increased risk of developing the associated vascular complications. Aim: To evaluate the potential of serum fluorescence levels of F-AGEs as screening tools to distinguish between type 2 diabetic patients with and without microvascular complications such as retinopathy, neuropathy. Materials and Methods: This cross-sectional study was conducted between June 2016 and June 2017, included 95 type 2 diabetic patients with more than 1 year of diabetes duration. Fasting blood glucose, glycated haemoglobin and total protein levels were estimated by automated methods. Serum F-AGEs were estimated by using a simple spectrofluorometric method. Microvascular complications due to diabetes mellitus were studied in each patient from medical records data on fundus examination for retinopathy and touch, vibration sensation detection for neuropathy. Diabetic patients were categorised into two groups as those without microvascular complications and those with microvascular complications-retinopathy and neuropathy. Statistical tests used for comparisons between groups were chi-square test for gender distribution, independent t-test for other parameters and Pearson's correlations. The p-value <0.05 indicated significant difference between variables. Results: Mean age of the population was 55.1 +/- 5.3 years. Diabetic patients with microvascular complications (n=26) in the form of retinopathy, neuropathy had significantly higher levels of serum F-AGEs with mean 7.4 +/- 1.8 AU/g protein compared with diabetic patients without complications with mean value 1.5 +/- 0.7 AU/g protein (p<0.01). Conclusion: Two categories of serum fluorescent AGE values, without overlap, could be distinguished between diabetic patients with and without complications. Measurement of serum F-AGEs products has the potential to emerge as a simple, valuable screening tool to distinguish between diabetic patients with and without microvascular complications.

1 December 2025 in Asian Journal of Pharmaceutics
Verified
Other
Open access
PDF file
Nivedita L. RaoNivedita L. Rao
Nivedita L. Rao
The Asian Journal of Pharmaceutics is a peer-reviewed open-access medical journal published by Medknow Publications on behalf of the B.R. Nahata Smriti Sansthan (Memorial Trust) (Mandsaur, India). Articles address topics in pharmaceutics, biopharmaceutics, pharmaceutical chemistry, pharmacognosy, pharmacology, pharmaceutical analysis, pharmacy practice, and clinical and hospital pharmacy.

29 May 2021
Verified
Book Chapter
Closed access
Nivedita L. RaoNivedita L. Rao
Nivedita L. Rao
GKGreeshma B. Kotian
Greeshma B. Kotian
HKH. Prathapchandra Kedilaya
H. Prathapchandra Kedilaya
Green laboratories that reduce the impact on the environment by promoting sustainable best practices such as waste reduction, have gained importance in recent times. Researchers have developed new technologies and validated a wide range of salivary biomarkers that can soon make the use of saliva a clinical reality. Saliva, like blood, contains an abundance of biomarkers and has tremendous potential to become an alternative diagnostic fluid to blood. Saliva collection method is noninvasive, painless, and convenient to subjects compared to the conventional blood collection process. This chapter explores the potential advantages of using saliva as an alternative to blood, in terms of the volume and effect of the biomedical waste generated. Experimental evidence and theoretical explanation to how saliva-based diagnostics can substantially decrease the volume of potentially infectious, pathological hazardous waste generated by laboratories and impact global waste management strategies, are illustrated in this chapter.